Prediction of disease-free survival by the PET/CT radiomic signature in non-small cell lung cancer patients undergoing surgery

[1]  Kujtim Latifi,et al.  Imaging features from pretreatment CT scans are associated with clinical outcomes in nonsmall‐cell lung cancer patients treated with stereotactic body radiotherapy , 2017, Medical physics.

[2]  Carsten Brink,et al.  Survival prediction of non-small cell lung cancer patients using radiomics analyses of cone-beam CT images. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[3]  Tong-fu Yu,et al.  Comparison of a radiomic biomarker with volumetric analysis for decoding tumour phenotypes of lung adenocarcinoma with different disease-specific survival , 2017, European Radiology.

[4]  L Cozzi,et al.  PET Radiomics in NSCLC: state of the art and a proposal for harmonization of methodology , 2017, Scientific Reports.

[5]  Philippe Lambin,et al.  Quantitative radiomics studies for tissue characterization: a review of technology and methodological procedures , 2017, The British journal of radiology.

[6]  J. Fontaine,et al.  Efficacy of lymph node dissection during robotic-assisted lobectomy for non-small cell lung cancer: retrospective review of 159 consecutive cases. , 2016, Journal of thoracic disease.

[7]  A. D’Andrilli,et al.  Lymph node dissection after pulmonary resection for lung cancer: a mini review. , 2016, Annals of translational medicine.

[8]  Raymond H Mak,et al.  CT-based radiomic analysis of stereotactic body radiation therapy patients with lung cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  V. Goh,et al.  Imaging Heterogeneity in Lung Cancer: Techniques, Applications, and Challenges. , 2016, AJR. American journal of roentgenology.

[10]  Vishwa Parekh,et al.  Radiomics: a new application from established techniques , 2016, Expert review of precision medicine and drug development.

[11]  Ronald Boellaard,et al.  Repeatability of Radiomic Features in Non-Small-Cell Lung Cancer [18F]FDG-PET/CT Studies: Impact of Reconstruction and Delineation , 2016, Molecular Imaging and Biology.

[12]  D. Townsend,et al.  Impact of Image Reconstruction Settings on Texture Features in 18F-FDG PET , 2015, The Journal of Nuclear Medicine.

[13]  Irène Buvat,et al.  Tumor Texture Analysis in PET: Where Do We Stand? , 2015, The Journal of Nuclear Medicine.

[14]  Ji-Hoon Jung,et al.  Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non–Small Cell Lung Cancer , 2015, Clinical nuclear medicine.

[15]  Benjamin Haibe-Kains,et al.  Radiomic feature clusters and Prognostic Signatures specific for Lung and Head & Neck cancer , 2015, Scientific Reports.

[16]  Waranya Rattanavipapong,et al.  Methodological Variation in Economic Evaluations Conducted in Low- and Middle-Income Countries: Information for Reference Case Development , 2015, PloS one.

[17]  P. Marsden,et al.  False Discovery Rates in PET and CT Studies with Texture Features: A Systematic Review , 2015, PloS one.

[18]  P. Lambin,et al.  CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[19]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[20]  Georg Schramm,et al.  Quantitative assessment of the asphericity of pretherapeutic FDG uptake as an independent predictor of outcome in NSCLC , 2014, BMC Cancer.

[21]  Florent Tixier,et al.  Visual Versus Quantitative Assessment of Intratumor 18F-FDG PET Uptake Heterogeneity: Prognostic Value in Non–Small Cell Lung Cancer , 2014, The Journal of Nuclear Medicine.

[22]  S Senan,et al.  2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[24]  Fumihiro Tanaka,et al.  Recurrence after surgery in patients with NSCLC. , 2014, Translational lung cancer research.

[25]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[26]  J. Crowley,et al.  The revised TNM staging system for lung cancer. , 2009, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.

[27]  Ping Yang,et al.  Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. , 2008, Mayo Clinic proceedings.

[28]  W. Rom,et al.  Survival after surgery in stage IA and IB non-small cell lung cancer. , 2008, American journal of respiratory and critical care medicine.

[29]  T. Waldmann,et al.  Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[30]  M. Brundage,et al.  Prognostic factors in non-small cell lung cancer: a decade of progress. , 2002, Chest.

[31]  Frank C. Detterbeck,et al.  The Eighth Edition Lung Cancer Stage Classification , 2017, Chest.

[32]  Florent Tixier,et al.  Development of a nomogram combining clinical staging with 18F-FDG PET/CT image features in non-small-cell lung cancer stage I–III , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  M. Kris,et al.  Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. , 2014, The Lancet. Oncology.

[34]  L. Leslie,et al.  A decade of progress. , 1969, Minnesota medicine.